Steven D. Singer


Chair, Transactional Department

Singer, Steven D.

Steven Singer has more than three decades of experience as a corporate attorney who has represented clients in a wide range of transactions. He has advised numerous public and private companies in the life sciences industry, focusing on joint ventures and strategic alliances, corporate and securities law, public offerings and venture capital transactions. Mr. Singer is consistently recognized in the areas of corporate and life sciences for successfully handling complex deals and collaborations in the technology transactions and licensing sector.


Mr. Singer has focused his practice in the life sciences industry for more than three decades. He has served as counsel for public and private companies in the life sciences sector, including biotechnology, medical device and pharmaceutical companies. His practice focuses on joint ventures and strategic alliances, corporate and securities laws, public offerings and venture capital transactions.

Mr. Singer has worked with the following public company clients, among others: Achillion, Agios, Aveo, Catabasis, Cerulean, Curis, Editas, Infinity, Karyopharm and Syros. Representative private company clients include Constellation, Cydan, Decibel, Fulcrum, Visterra and X-Chem. Mr. Singer has also worked with pharmaceutical companies, including Bristol Myers Squibb, Novartis and Wyeth.

Mr. Singer has also worked with New York-based medical and academic institutions in the establishment and operation of an independent, nonprofit genome sequencing center, the Tri-Institutional Therapeutics Discovery Institute and Bridge Medicines.

Honors & Awards

  • Recognized as one of the world's leading life sciences lawyers in the 2008-2016 editions of Who's Who Legal: The International Who's Who of Life Sciences Lawyers; also recognized in the 2011-2016 edition of Who's Who Legal: The International Who's Who of Business Lawyers
  • Recognized as a national leader in the life sciences: corporate/commercial field in the 2008-2017 editions of Chambers Global: The World's Leading Lawyers for Business
  • Selected by his peers for inclusion in the 2006-2018 editions of the Best Lawyers in America, and was named New York Biotechnology and Life Sciences Practice Lawyer of the Year for 2018, 2016 and 2011, New York Corporate Law Lawyer of the Year for 2017, and New York Mergers and Acquisitions Law Lawyer of the Year for 2015 
  • Listed in each edition of Chambers USA: America's Leading Lawyers for Business since 2003; recognized each year for his exceptional corporate/M&A practice and also for his life sciences commercial work in 2007-2009 and 2011-2017 editions. Sources describe Mr. Singer as a "phenomenal lawyer" who "knows the industry backwards and forwards."
  • Named an elite "Leading Lawyer" in the areas of life sciences and intellectual property: patent licensing and transactional by The Legal 500 United States. In the guidebook, a source stated that he is "absolutely outstanding on general corporate matters, strategy and all other areas."
  • Shortlisted for Finance & Transactional Attorney of the Year: Corporate in 2017 and recognized as a Life Sciences Star for outstanding transactional work in the 2012-2017 editions of LMG Life Sciences
  • Named a "New York Super Lawyer" in the 2011-2017 editions of Metro Edition magazine
  • Named a 2013-2016 leading practitioner in patent law by IAM Patent 1000: The World's Leading Patent Practitioners
  • Selected as one of the nation's most highly recommended corporate M&A attorneys in the PLC Cross-Border Mergers and Acquisitions Handbook 2007/08
  • Ranked as a leader in the US life sciences commercial and partnering category in the 2006/07, 2007/08 and 2009/2010 editions of the PLC Cross-border Life Sciences Handbook; also highly recommended for his corporate practice in 2006/07 and 2007/08
  • Named a "New England Super Lawyer" (formerly "Massachusetts Super Lawyer") in securities and venture finance in the 2004-2008 issues of Boston Magazine

Publications & News


March 20, 2018

WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration.

March 16, 2018

WilmerHale Recognized for Outstanding International Lawyers and Practices in Chambers Global 2018

In the 2018 edition of Chambers Global, 33 WilmerHale lawyers were named among “The World's Leading Lawyers for Business."

March 14, 2018

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

January 26, 2018

WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

Karyopharm Therapeutics Inc. announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions.

December 29, 2017

WilmerHale Represents Arsanis in Closing of Initial Public Offering

Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option.

December 15, 2017

WilmerHale Reps Decibel Therapeutics in Strategic Collaboration With Regeneron

On November 29, 2017, Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. announced a collaboration to discover and develop new potential therapeutics to protect, repair and restore hearing.

November 17, 2017

WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of $2.75 per share.

November 7, 2017

LMG Life Sciences 2017 Honors WilmerHale With Top Rankings

LMG Life Sciences has recognized WilmerHale among the nation's leading life sciences law firms in its 2017 rankings, citing the firm's Life Sciences Practice as “renowned for its range and multidisciplinary teams that counsel clients in technology, pharmaceutical and medical device companies as well as investment banks and venture capitalists.”

October 26, 2017

WilmerHale Reps MacroGenics in Global Collaboration and Licensing Agreement With Incyte

MacroGenics, Inc. and Incyte Corporation announced that they have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).

September 19, 2017

LMG Life Sciences Names WilmerHale Life Cycle Firm of the Year and Lisa Pirozzolo General Patent Litigator of the Year

Lawyers from across the United States and Canada gathered on September 13 at the Essex House in New York to celebrate the annual LMG Life Sciences Awards, recognizing the 2017 top firms and legal professionals in the life science industry.

Speaking Engagements

October 10, 2017

Powering Possibilities 2017

Boston, Massachusetts

February 13-14, 2013

Boston Biotech Conference: CEO New York Conference

New York, New York

March 29-30, 2007

Advanced Licensing Agreements 2007

New York, New York

March 29, 2007

PLI News "Advanced Licensing Agreements" 2007

New York, New York

June 20-22, 2005

BIO 2005

Philadelphia, Pennsylvania

April 13, 2005

WilmerHale Event - From Concept to Collaboration: The Life Cycle of Agreements for Life Sciences Companies

Boston, Massachusetts

Recent Highlights

  • Over the last several years, representation of the following companies in their initial public offerings and follow-on offerings: Agios, Catabasis, Cerulean, Editas, Kala, Karyopharm and Syros
  • Representation of New York-based academic and medical institutions in the establishment of research and development vehicles—Tri-I Therapeutics Discovery Institute and Bridge Medicines
  • Representation of MacroGenics in its alliances with Janssen, Servier, Takeda and Incyte
  • Representation of an independent, nonprofit genome sequencing center and consortium in its organization as a 501(c)(3) organization with multiple medical and academic institutions as members
  • Representation of Constellation in its collaboration with Genentech
  • Representation of Decibel in its collaboration with Regeneron

Professional Activities

Mr. Singer is a member of the American Bar Association, the Biotechnology Industry Organization and the Massachusetts Biotechnology Council.

Community Involvement

Mr. Singer serves on the Boards of Directors of the New York Genome Center and The Possible Project.


Skip Navigation Links.


JD, magna cum laude, Harvard Law School, 1979, Harvard Law Review

BA, summa cum laude, Tufts University, 1976

Bar Admissions

New York


Skip Navigation Links.